Table 1.

GPA study cohort

Age (yr)33 (18–60)
 African American7
Meets ACR criteria for diagnosis100 (27/27)
Male sex89 (24/27)
Sinus involvement48 (13/27)
Pulmonary involvement82 (22/27)
Hemoptysis/respiratory failure37 (10/27)
Renal involvement85 (23/27)
ARF33 (9/27)
Preceding CKD0
Hypertension (chronic)41 (11/27)
Biopsy evidence of vasculitis (total)66 (12/18)
 Kidney22 (4/18)
 Lung33 (6/18)
 Sinus11 (2/18)
 Skin28 (5/18)
PR3-ANCA level (U/ml) (n=9) 61 (10–113); 1:640 (1:160–1:1280)
C-reactive protein (n=7)7.8 (2.1–19.4)
Therapeutic intervention (cyclophosphamide, steroids, rituximab, methotrexate, azathioprine)100 (18/18)
Abnormal chest CT scan or radiograph92 (11/12)
Abnormal sinus CT scan80 (4/5)
Abnormal chest or sinus imaging scan100 (12/12)
Concurrent anti-GBM disease0
Other antibody (ANA, dsDNA, Smith, RNP, Ro, La, SCL-70, Jo-1, GBM antibodies)0 (0/8)
  • Data are presented as the median (range) or percentage (proportion). Comorbidity percentages may be underestimated due to incomplete background information from patients diagnosed at civilian hospitals. International Classification of Diseases, Ninth Revision codes cannot fully compensate for this limitation, because sometimes the final diagnosis is the only code listed when billing outside the military is not required. GPA, granulomatosis with polyangiitis; ACR, American College of Rheumatology; PR3, proteinase-3; CT, computed tomography; GBM, glomerular basement membrane; ANA, antinuclear antibody; dsDNA, double-stranded deoxyribonucleic acid; RNP, ribonucleoprotein; SLC-70, topoisomerase I.